Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy

Vascular Medicine

Volumn 9, Issue 1, 2004, Pages 18-25

  Hiatt, William R ^a   Hirsch, Alan T ^b   Cooke, John P ^c   Olin, Jeffrey W ^d   Brater, D Craig ^e   Creager, Mark A ^f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Intermittent claudication; Peripheral vascular disease; Randomized controlled trial; Treatment

Indexed keywords

CILOSTAZOL; FLUCONAZOLE; ITRACONAZOLE; KETANSERIN; KETOCONAZOLE; MICONAZOLE; N [2 [4 (5H DIBENZO[A,D]CYCLOHEPTEN 5 YLIDENE)PIPERIDINO]ETHYL] 1 FORMYLISONIPECOTAMIDE; PLACEBO; PROTEINASE INHIBITOR; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; WARFARIN;

AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CHOLINERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; COMPARTMENT MODEL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; EXERCISE TOLERANCE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT JUICE; HEART INFARCTION; HEMODYNAMICS; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; PRIORITY JOURNAL; PULSE RATE; QT PROLONGATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUPINE POSITION; SYMPTOM; THROMBOCYTE AGGREGATION; TIME; TREADMILL EXERCISE; VASOCONSTRICTION; WALKING; XEROSTOMIA;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; ISONIPECOTIC ACIDS; MALE; MIDDLE AGED; QUALITY OF LIFE; RECEPTOR, SEROTONIN, 5-HT2A; WALKING;

EID: 3042815676     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x04vm520oa     Document Type: Article

References (18)

1. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000; 31: S1-S296.
2. Fowkes FG, Housley E, Cawood EH et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-92.
3. Criqui MH, Fronek A, Klauber MR et al. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation 1985; 71: 516-22.
4. McGrae MM, Greenland P, Liu K et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286: 1599-606.
5. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
6. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 1996; 155: 1053-59.
7. Regensteiner JG, Ware JE Jr, McCarthy WJ et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50 :1939-46.
8. Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg 2002; 36: 1283-91.
9. Kroeze WK, Kristiansen K, Roth BL. Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem 2002; 2: 507-28.
10. Vanmolkot FH, de Hoon JN, Barrington P et al. Non-invasive assessment of selective 5-HT(1B/1D)-receptor agonist-induced peripheral vascular effects in humans: comparison of different techniques. Eur J Clin Pharmacol 2002; 58: 303-308.
11. Clement DL, Duprez D. Effect of ketanserin in the treatment of patients with intermittent claudication: results from 13 placebo-controlled parallel group studies. J Cardiovasc Pharmacol 1987; 10 suppl 3: S89-S95.
12. Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. BMJ 1989; 298: 424-30.
13. Kihara H, Koganei H, Hirose K et al. Antithrombotic, activity of AT-1015, a potent 5-HT2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Eur J Pharmacol 2001; 433: 157-62.
14. Labs KH, Dormandy JA, Jaeger KA et al. Transatlantic conference on clinical trial guidelines in PAOD (peripheral arterial occlusive disease) clinical trial methodology. Eur J Vasc Endovasc Surg 1999; 18: 253-65.
15. Hiatt WR, Nawaz D, Regensteiner J, Hossack K. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulm Rehabil 1988; 12: 525-32.
16. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP, and the Vascular Clinical Trials Group. Clinical trials for claudication: assessment of exercise performance, functional status, and clinical endpoints. Circulation 1995; 92: 614-21.
17. Davey PP, Barlow C, Hart G. Prolongation of the QT interval in heart failure occurs at low but not at high heart rates. Clin Sci 2000; 98: 603-10.
18. Yildiz O, Smith JR, Purdy RE. Minireview. Serotonin and vasoconstrictor synergism. Life Sci 1998; 19: 1723-32.